- Business
- Childbirth & Education
- Legal Formalities
- Motoring
- Other
- Pensions & Benefits
- Property & Accommodation
- Taxes
- Airports and Airlines Spain
- Paramount Theme Park Murcia Spain
- Corvera International Airport Murcia Spain
- Join us for Tea on the Terrace
- When Expat Eyes Are Smiling
- Meet Wincham at The Homes, Gardens & Lifestyle Show, Calpe
- QROPS 2014
- Spain Increases IHT in Valencia & Murcia
- Removals to Spain v Exports from Spain
- The Charm of Seville
- Gibraltar Relations
- Retiro Park : Madrid
- Community Insurance in Spain
- Calendar Girls
- Considerations when Insuring your Boat in Spain
- QROPS – HMRC Introduces changes that create havoc in the market place
- QROPS – All Change From April 2012
- Liva & Laia : 15th November
Danish pharmaceutical group Lundbeck said on Friday it would start clinical phase II trials with drug candidate Lu as augmentation treatment in Alzheimer's disease.
"The purpose of this study is to investigate if Lu after 24 weeks improves cognition and functional outcomes inpatients with moderate Alzheimer's disease that are already in treatment with donepezil" Lundbeck said in a statement.
In November 2008, Lundbeck initiated a clinical phase IItrial with Lu AE58054 in schizophrenia.
Lundbeck currently generates the majority of its revenue from Cipralex, sold in the United States as Lexapro.
Be the first to comment on this Story !!